Stock Analysts’ Ratings Reiterations for August, 21st (AMAT, AMPE, DKL, ECI, GGB, IRF, LZB, MDCO, MWE, NBL)
Applied Materials (NASDAQ:AMAT) had its strong-buy rating reiterated by analysts at S&P Equity Research.
Ampio Pharmaceuticals (NASDAQ:AMPE) had its buy rating reissued by analysts at Aegis.
Delek Logistics Partners (NYSE:DKL) had its buy rating reissued by analysts at Bank of America. The firm currently has a $39.00 price target on the stock, down from their previous price target of $45.00.
Enercare (TSE:ECI) had its sector perform rating reiterated by analysts at Scotiabank.
Gerdau (NYSE:GGB) had its neutral rating reissued by analysts at Zacks. The firm currently has a $6.00 price target on the stock. Zacks’ analyst wrote, “Gerdau’s net income declined 1.9% year over year in second-quarter 2014, with earnings coming in at $0.10 per ADR. Revenues grew 5.7% due to healthy performance in North America, Special Steel and Iron Ore business operations. However, weak domestic demand for steel and lower exports affected the company’s Brazilian operations while business in Latin America suffered from slower economic growth. Steel shipments were down 2.4% while production grew a meagre 0.5%. Gross margin was down 150 basis points. However, planned investments to improve manufacturing techniques, production capacities and raw material resources will help Gerdau to capitalize on the growing steel demand worldwide. Considering the above factors, we maintain a Neutral recommendation on the company. “
International Rectifier Corp. (NYSE:IRF) had its average rating reissued by analysts at S&P Equity Research. They currently have a $21.25 price target on the stock, up from their previous price target of $19.14.
La-Z-Boy (NYSE:LZB) had its strong-buy rating reissued by analysts at Raymond James. Raymond James currently has a $28.00 target price on the stock, down from their previous target price of $32.00.
The Medicines Company (NASDAQ:MDCO) had its neutral rating reissued by analysts at Zacks. They currently have a $28.00 target price on the stock. Zacks’ analyst wrote, “The Medicines Co.’s second quarter EPS of $0.18 per share was below the year-earlier EPS of $0.44. Revenues rose 6.3% year over year to $183.8 million, but missed the Zacks Consensus Estimate of $185 million. Although Angiomax should continue growing, we remain concerned about the earlier-than-expected entry of generics. Meanwhile, we are encouraged to see that management is actively pursuing in-licensing deals and acquisitions to drive long-term growth. We are pleased with the company’s co-promotion deal with AstraZeneca. The Recothrom, ProFibrix and Incline deals also look good to us. The Tenaxis acquisition indicates the company’s efforts to diversify its portfolio and reduce its dependence on Angiomax. Meanwhile, Orbactiv’s recent approval is also a positive. We remain Neutral on the stock.”
Markwest Energy Partners (NYSE:MWE) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $79.00 target price on the stock. Zacks’ analyst wrote, “We are maintaining our Neutral recommendation on units of MarkWest Energy, given limited near term price upside. We continue to like MarkWest for its high-quality and diverse portfolio of midstream assets, as well as its proven track record of supporting producers in the growth of shale plays and its steady improvement in its liquidity/cash flow position. However, we think the current valuation is fair and adequately reflects the partnership’s future growth prospects. MarkWest’s core business – natural gas processing – is also faced with a higher degree of commodity price exposure than most MLPs. This is expected to further limit its ability to generate positive earnings surprises. As a result, our long-term total return expectation for MarkWest remains rather muted. “
Painted Pony Petroleum Limited (CVE:PPY) had its sector outperform rating reissued by analysts at Scotiabank.
Transocean LTD (NYSE:RIG) had its neutral rating reissued by analysts at Zacks. The firm currently has a $42.00 target price on the stock. Zacks’ analyst wrote, “We are maintaining our Neutral recommendation on Transocean shares, despite high debt. The company recently reported strong second quarter earnings on higher dayrates and reduced operating and maintenance costs. Moreover, Transocean expects a significantly lower operating cost in 2014 relative to the prior two years that is expected to drive its bottom line to a great extent. Transocean also has a technologically advanced and versatile offshore drilling fleet, strong backlog and considerable pricing power. Nevertheless, we expect Transocean shares to remain soft until it fully works its way through claims related to the BP oil spill. “
Raging River Exploration (CVE:RRX) had its sector outperform rating reissued by analysts at Scotiabank.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.